Genova Clinical Research is looking for subjects to participate in a clinical research study testing the safety and effectiveness of an investigational medication vs. placebo (an inactive substance) for subjects with irritable bowel syndrome with predominant diarrhea.
This study lasts approximately 10 weeks and has approximately 6 office visits. Study-related drugs (may include placebo), lab work, and study-related physical exams are provided to participants in this study at no cost. Compensation is available to qualified participants for each completed visit for time and travel.
Subjects interested in this study should:
If you are interested in finding out more about this study, please call us at (520) 219-6394. One of our staff will be happy to give you further information regarding this study and will schedule you an appointment so you may review the study in more detail with one of our study physicians.
Irritable Bowel Syndrome (IBS) is a very common gastrointestinal (GI) disorder that involves abdominal pain or discomfort with diarrhea, constipation or both. Genova Clinical Research is looking for subjects to participate in a clinical research study of an investigational drug vs. placebo (an inactive substance) for people with diarrhea predominant IBS.
This study lasts approximately 18 weeks and has approximately 5 office visits. Study-related drugs (may include placebo), lab work, and study-related physical exams are provided to participants in this study at no cost. Compensation is available to qualified participants for each completed visit for time and travel.
Subjects interested in this study should:
If you are interested in finding out more about this study, please call us at (520)219-6394. One of our staff will be happy to give you further information regarding this study and will schedule you an appointment so you may review the study in more detail with one of our study physicians. If you know of anyone that might be interested in this study, please feel free to pass this information along to them.
Receive study news and updates on Facebook and Twitter: